Summary of acotinib price in 2024

Acalabrutinib (Acalabrutinib, trade name: Kangkeqi) is a selective BTK inhibitor developed by AstraZeneca. The drug is primarily used to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. By blocking the action of abnormal proteins, acotinib helps prevent the spread of cancer cells, providing a new treatment option for MCL patients. In addition, the drug has shown good efficacy and safety in chronic lymphocytic leukemia (CLL). The launch of acotinib has brought more hope to relevant patients. It is understood that the price of the drug has always been one of the focuses of concern among patients. This article will introduce the price situation of acotinib in 2024.

Acotinib, as a targeted treatment drug for lymphoma, has been successfully launched in my country. The price of this drug is relatively high, with a box usually selling for tens of thousands of yuan. However, it is gratifying that acotinib has been included in my country's medical insurance directory, which has reduced the financial burden on patients to a certain extent.

However, it should be noted that medical insurance reimbursement policies may differ in different regions. Some regions may reimburse acotinib at a higher rate, while others may reimburse it at a lower rate. In addition, medical insurance reimbursement usually has certain conditions, such as patients need to meet certain disease diagnosis standards and treatment plans. Therefore, when purchasing acotinib, patients should first consult the local medical insurance bureau and hospital pharmacy to understand the specific reimbursement situation and conditions.

For patients with greater financial pressure, overseas generic drugs are also a good choice. Currently, there are multiple versions of generic versions of acotinib on the market. Among them, the version produced by Laos ASEAN Pharmaceutical has attracted much attention. The price of the medicine with the specification of 100mg*60 tablets is about more than 3,000 yuan. In Bangladesh, the version produced by Yaopin International is slightly more expensive, with drugs of the same specifications selling for about 6,000 yuan.

In general, although the price of acotinib is relatively high, patients can alleviate financial pressure to a certain extent through medical insurance and the choice of overseas generic drugs.